DADC
VIVO

D.A. Davidson & Co’s Meridian Bioscience Inc VIVO Stock Holding History

D.A. Davidson & Co’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-933
Closed -$24K – 2225
2013
Q4 		$24K Buy
+933
New +$22.9K ﹤0.01% 1507

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

D.A. Davidson & Co's VIVO Position: Q1 2014 in Review

D.A. Davidson & Co sold out of Meridian Bioscience Inc (VIVO) in Q1 2014, closing a stake of 933 shares — an estimated $24K sold.

D.A. Davidson & Co first reported a position in VIVO in Q4 2013 and held it in 1 quarter. The position peaked at $24K in Q4 2013. 166 funds tracked by Wall St. Rank hold VIVO as of Q1 2014.

  • D.A. Davidson & Co reported no remaining Meridian Bioscience Inc position as of Q1 2014 after selling out during the quarter.
  • D.A. Davidson & Co sold 933 Meridian Bioscience Inc shares in Q1 2014, an estimated $24K.
  • D.A. Davidson & Co first reported a position in Meridian Bioscience Inc in Q4 2013 and held it in 1 quarter.
  • D.A. Davidson & Co's Meridian Bioscience Inc position peaked at $24K in Q4 2013.
  • 166 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2014.

Based on D.A. Davidson & Co's 13F filing for Q1 2014, filed 5 May 2014.